Nelson Dusetti shared on LinkedIn:

“We are thrilled to announce a major advancement in transcriptomic signatures for predicting treatment sensitivity in pancreatic cancer, now extended to metastatic patients through fine needle aspiration (FNA) biopsies. This development broadens the application of the Pancreas View transcriptomic signature, initially validated in operable patients, to include all pancreatic cancer patients, marking a significant step toward more personalized and effective treatments.”

Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer

Authors:Nicolas Fraunhoffer, Carlos Teyssedou, Patrick Pessaux, Martin Bigonnet, Nelson Dusetti, Juan Iovanna

Source: Nelson Dusetti/LinkedIn

More posts featuring Nelson Dusetti on oncodaily.com

Nelson Dusetti is Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.

Nelson Dusetti: A major advancement in transcriptomic signatures for predicting treatment sensitivity in pancreatic cancer